Given that we did not observe upregulation of Tcf1/7, Myc, and cyclin D1 in BRCA2-null ovarian cancer cells, the potential absence of these prosurvival mechanisms may very well contribute to the improved survival observed in patients with BRCA2 ovarian cancer (15). The gene discussed is BRCA2; the disease is ovarian carcinoma.